Cable Hill Partners, LLC Immuno Gen, Inc. Transaction History

Cable Hill Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$3.94 - $9.7 $622 - $1,532	-158 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $3,603 - $4,717	-419 Reduced 72.62%	158 $1,000
Q4 2017 Feb 22, 2018	SELL	$5.07 - $7.92 $583 - $910	-115 Reduced 16.62%	577 $4,000
Q3 2017 Oct 27, 2017	BUY	$5.4 - $8.47 $3,736 - $5,861	692	692 $5,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Cable Hill Partners, LLC with notifications on news.